- Home
- ATNF vs GCTK Comparison
ATNF vs GCTK Comparison
Compare ATNF & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- GCTK
- Stock Information
- Founded
- ATNF 2016
- GCTK 2001
- Country
- ATNF United States
- GCTK United States
- Employees
- ATNF N/A
- GCTK N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- GCTK Medical/Dental Instruments
- Sector
- ATNF Health Care
- GCTK Health Care
- Exchange
- ATNF Nasdaq
- GCTK Nasdaq
- Market Cap
- ATNF 5.7M
- GCTK 5.1M
- IPO Year
- ATNF N/A
- GCTK N/A
- Fundamental
- Price
- ATNF $1.46
- GCTK $0.09
- Analyst Decision
- ATNF
- GCTK
- Analyst Count
- ATNF 0
- GCTK 0
- Target Price
- ATNF N/A
- GCTK N/A
- AVG Volume (30 Days)
- ATNF 1.1M
- GCTK 126.3M
- Earning Date
- ATNF 02-13-2025
- GCTK 11-14-2024
- Dividend Yield
- ATNF N/A
- GCTK N/A
- EPS Growth
- ATNF N/A
- GCTK N/A
- EPS
- ATNF N/A
- GCTK N/A
- Revenue
- ATNF N/A
- GCTK N/A
- Revenue This Year
- ATNF N/A
- GCTK N/A
- Revenue Next Year
- ATNF $54.15
- GCTK N/A
- P/E Ratio
- ATNF N/A
- GCTK N/A
- Revenue Growth
- ATNF N/A
- GCTK N/A
- 52 Week Low
- ATNF $1.16
- GCTK $0.06
- 52 Week High
- ATNF $17.75
- GCTK $4.95
- Technical
- Relative Strength Index (RSI)
- ATNF 39.69
- GCTK 34.06
- Support Level
- ATNF $1.43
- GCTK $0.06
- Resistance Level
- ATNF $1.67
- GCTK $0.14
- Average True Range (ATR)
- ATNF 0.13
- GCTK 0.04
- MACD
- ATNF 0.00
- GCTK 0.01
- Stochastic Oscillator
- ATNF 21.82
- GCTK 11.89
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.